Skip to content
Open access

Clonal hematopoiesis and cytopenias following CAR19 therapy

Nov 2026 · Nature Genetics · Vol 58, pp. 2895 - 2909 · 0 citations · 112 references
Medicine

Abstract

CD19-directed chimeric antigen receptor T cell therapy (CAR19) improves survival in relapsed/refractory large B cell lymphoma compared with immunochemotherapy with intent for autologous hematopoietic cell transplantation (autoHCT). However, major toxicities include prolonged cytopenias, infection and secondary hematologic malignancies. Here, to investigate these complications, we studied patients with lymphoma receiving CAR19 and compared clinical outcomes to propensity-matched autoHCT-treated controls. CAR19-treated patients exhibited impaired immune reconstitution and increased infection. Bone marrow analysis showed that prolonged post-CAR cytopenias are associated with clonal cytopenias of undetermined significance and interferon-mediated inflammation. Clonal hematopoiesis (CH) commonly expanded following CAR19 infusion and was associated with impaired immune reconstitution and treatment-related myeloid malignancy (tMN). Post-CAR tMN was molecularly and clinically comparable to post-autoHCT tMN. Single-cell DNA analysis revealed mostly independent CH clones, while CAR integration into CH-mutant T cells occurred frequently and may drive expansion and persistence. Together, these findings implicate CH expansion and marrow inflammation in key CAR19-associated toxicities. This study shows that clonal hematopoiesis expands after chimeric antigen receptor (CAR) T cell therapy and contributes to secondary myeloid cancers. In addition, the CAR vector frequently integrates into pre-existing clonal hematopoiesis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.